DUBLIN--(BUSINESS WIRE)--The "COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The healthcare systems have been struggling to manage the COVID-19 patient population globally and hence the medical researchers are racing to find a solution to the pandemic. According to this latest publication, the leading areas of research include antibodies, protein-based vaccines, antiviral, drug repurposes, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies. While more than 50% of the therapies being developed are in the preclinical stage, government initiatives, such as Emergency Use Authorization (EUA) by FDA, is expected to accelerate the research and development (R&D) process.
Based on healthcare options, the COVID-19 impact assessment is analyzed into diagnostics and treatments areas. The market opportunity of these products is estimated to reach USD 13.9 billion in 2025. The diagnostics segment is further divided into PCR-based testing and antibody testing. The treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide.
Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having the most number of confirmed cases as well as deaths, globally. Other most affected nations include the U.K., Spain, France, Italy, Brazil, Germany, and India among others. Further, almost all the affected nations have experienced rapid economic decline leading GDP decline, an increase in unemployment rates, and an increase in the inflation rates.
To overcome the situation, governments have imposed restriction on people movement as well as invested resources towards dealing with crisis and supporting all research and medical efforts towards developing a treatment option. The U.S., Canada, the U.K., Germany, China, and India are some of the key nations leading the research and production efforts geared towards developing COVID-19 medication.
Companies Mentioned
-
AbbVie Corporation
-
Abbott Laboratories
-
AstraZeneca Plc
-
Athersys Inc.
- Becton, Dickinson and Company
-
CTI Biopharma Corporation
-
Celularity Inc.
-
Eli Lilly and Company
-
Gilead Sciences Inc.
-
GlaxoSmithKline
-
Inovio Pharmaceuticals Inc.
- Johnson & Johnson
-
Medicago Inc.
-
Moderna Inc.
-
Novavax Inc.
- OncoImmune Inc.
- Pfizer Inc.
- Pluristem Therapeutics
-
Roche Holding AG
-
Sanofi S.A.
- Sorrento Therapeutics Inc.
- Takeda Pharmaceuticals Company Ltd
- Thermo Fisher Scientific Inc.
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Coronavirus: Epidemiology
3.1. About Coronavirus
3.2. Transmission & Symptoms
3.3. Prevention
3.4. Epidemiology
4. Executive Summary
4.1. Introduction
4.2. Global Economic Impact
4.3. COVID-19 Response
4.4. COVID-19 Research Pipeline
4.5. COVID-19 Pipeline Development Challenges
4.6. Key Companies
5. Covid-19: Impact on Healthcare Industry
5.1. Introduction
5.2. Key Trends & Impact on Healthcare Subsegments
5.3. Diagnostics
5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis
5.3.1.2. Restraints
5.3.1.3. Key Companies
5.3.2. Antibody Testing / Serological Testing
5.3.2.1. Advantages Over Molecular Tests
5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
5.3.2.3. Restraints
5.3.2.4. Key Companies
5.4. Therapies
5.4.1. Vaccines
5.4.2. Immunotherapies (Antibodies)
5.4.2.1. Monoclonal Antibody
5.4.2.2. T-Cell Therapy
5.4.2.3. Potential Game Changers: Antibodies
5.4.2.3.1. Ilaris (Canakinumab)
5.4.2.3.2. Sylvan (Siltuximab)
5.4.2.3.3. Lenzilumab
5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)
5.4.2.3.5. Tocilizumab
5.4.3. Antivirals
5.4.3.1. Potential Game Changers
5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)
5.4.3.1.2. Remdesivir
5.4.4. Cell-Based Therapies
5.4.5. Other Therapies
5.4.5.1. Plasma Therapy
5.4.5.2. Devices
6. Geography Impact Assessment
6.1. Introduction
6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine
6.2. North America
6.3. Europe
6.4. APAC
6.5. Rest of the World
7. Competitive Landscape
7.1. Introduction
7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures
7.3. R&D Updates
7.4. Auhrozation / Approvals
7.5. Donations Made
7.6. Funding Received
7.7. Capacity Expansion
7.8. Other Growth Strategies
8. Company Updates
For more information about this report visit https://www.researchandmarkets.com/r/s8qfaq
